Heterogeneity in primary tumors and corresponding metastases: could it provide us with any hints to personalize cancer therapy?
Heterogeneity in primary tumors and corresponding metastases: could it provide us with any hints to personalize cancer therapy?
复制标题
DOI：
10.2217/pme.10.81
复制
发表时间：
2011-03-01
影响因子：
2.3
通讯作者：
Teng, Lisong
中科院分区：
文献类型：
--
作者：
Jin, Ketao;He, Kuifeng;Teng, Lisong
患者间对抗癌药物的反应差异与不同的临床结果有关，这部分是由于患者之间的个体差异。许多研究人员希望，肿瘤的异质性将有助于揭示抗癌治疗反应中患者间差异的潜在机制。大量研究表明，肿瘤内存在异质性，原发肿瘤和相应转移的肿瘤在不同水平存在异质性，并表明这种异质性可能是抗癌治疗反应的潜在决定因素。本文讨论了肿瘤的异质性，重点讨论了原发肿瘤和相应转移的异质性及其对抗癌治疗反应的影响。此外，本文还提出了基于肿瘤部位的转移性肿瘤患者个体化治疗的设想，并提出了利用患者来源的肿瘤组织异种移植模型来实现这一设想的策略。
Interpatient variability in response to anticancer drugs is associated with different clinical outcomes, which is partially owing to the individual differences among patients. Many investigators have hoped that tumor heterogeneity would help to reveal the underlying mechanism of interpatient variability in response to anticancer therapy. Numerous studies have demonstrated the presence of intratumor heterogeneity and the heterogeneity in primary tumors and corresponding metastases in a wide range of tumors at different levels and have indicated that the heterogeneity might make sense as a potential determinant of anticancer therapy response. This article discusses tumor heterogeneity, focusing on the heterogeneity in primary tumors and corresponding metastases as well as the effect on anticancer therapy response. Furthermore, an idea of tumor-site-based personalized cancer therapy for patients with metastatic malignancies was hypothesized, and a strategy using a patient-derived tumor tissue xenograft model to realize this idea is also proposed in this article.